Cannabis Clinical Trial
Official title:
A Double Blind, Sham Controlled Trial of Excitatory rTMS to the Left Dorsolateral Pre-Frontal Cortex to Reduce Cannabis-Cue Induced Craving and Impulsive Decision Making in Cannabis Use Disordered Participants.
NCT number | NCT02567344 |
Other study ID # | Pro00047358 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 2015 |
Est. completion date | March 2016 |
Verified date | May 2018 |
Source | Medical University of South Carolina |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a double-blind, crossover trial that will recruit a cohort of non-treatment seeking Cannabis use disordered participants. Participants will then undergo either active, or sham rTMS to the LDLPFC, and cue-induced craving, and risky decision making will be assessed.
Status | Completed |
Enrollment | 18 |
Est. completion date | March 2016 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: 1. Participants must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments. 2. Participants must be between the ages of 18 and 60. 3. Participants must meet DSM-V criteria for Cannabis Use Disorder, with use of at least 20 days/month. 4. Participants must agree to abstinence from Cannabis for at least 24 hours prior to each visit. 5. Participants must have a Positive UDS for cannabis (confirming they are regular users), and a negative salivary cannabis test (Confirming no use within 10-14 hours) Exclusion Criteria: 1. Participants must not be pregnant and participate in the study. 2. Participants must not test positive for any substance other than cannabis on UDS. 3. Participants must not meet criteria for any other Substance Use Disorders with the exception of Nicotine Use Disorder. 4. Participants must not be on any medications that have central nervous system effects. 5. Participants Must not have a history of/or current Psychotic disorder. 6. Participants must not have a history of Dementia or other cognitive impairment. 7. Participants must not have active suicidal ideation, or suicide attempt within the past 90 days. 8. Participants must not have any contraindications to receiving rTMS as assessed by the TMS safety sheet. 9. Participants must not have any unstable general medical conditions. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Medical University of South Carolina |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Marijuana Craving Questionnaire (MCQ) | The MCQ will be given before and after a marijuana-cue paradigm, and the primary outcome will be the change score from pre to post. | 15 Minutes | |
Secondary | The Balloon Aptitude Response Task (BART) | The BART will be given pre, and post rTMS. Number of corrected pumps, and number of burst balloons will be collected. | 30 Minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT04199468 -
THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis
|
Phase 1 | |
Completed |
NCT04587700 -
Analgesic Consumption in Chronic Marijuana Users Following Orthopedic Trauma Surgery
|
||
Not yet recruiting |
NCT05899946 -
An Integrated Program to Promote Anti-cannabis Messages
|
N/A | |
Active, not recruiting |
NCT02735954 -
Colorado Marijuana Users Health Cohort
|
||
Completed |
NCT00842985 -
Dronabinol Interactions in Humans
|
N/A | |
Completed |
NCT04124432 -
Behavioral Pharmacology of Cannabis and Nicotine
|
Phase 1 | |
Active, not recruiting |
NCT04693884 -
Cannabis Inhalation: Effects on Cardiovascular Function During Rest and Exercise
|
Early Phase 1 | |
Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
Active, not recruiting |
NCT03560934 -
Tetrahydrocannabinol (THC) and Sleep
|
Early Phase 1 | |
Recruiting |
NCT04704271 -
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
|
Phase 1 | |
Withdrawn |
NCT03245658 -
The Effect of Cannabis in Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT04911127 -
Therapeutic Response of Cannabidiol in Rheumatoid Arthritis
|
Phase 1 | |
Not yet recruiting |
NCT05999383 -
Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
|
Phase 2 | |
Recruiting |
NCT04429568 -
THC Crossover Study
|
N/A | |
Completed |
NCT05554146 -
Pain Inflammation and Cannabis in HIV
|
N/A | |
Not yet recruiting |
NCT05320367 -
A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users
|
Phase 1/Phase 2 | |
Terminated |
NCT03251326 -
Nabilone in Cannabis Users With PTSD
|
Phase 1/Phase 2 | |
Completed |
NCT00176085 -
Pharmacokinetics of THCCOOH and Its Acyl-glucuronide After Intravenous Administration of THCCOOH
|
Phase 1 | |
Enrolling by invitation |
NCT06235632 -
Responsible Marijuana Sales Practices to Reduce the Risk of Selling to Intoxicated Customers
|
N/A |